Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

FDA approves Pletal for intermittent claudication

Jan. 18, 1999

FDA approves home use of Lovenox in patients with potentially life-threatening blood clots

Jan. 8, 1999

Potent thrombin inhibitors with heterocyclic structure synthesized at Lilly

Jan. 7, 1999

Another series of heterocyclic thrombin inhibitors revealed by Lilly

Jan. 5, 1999

Thrombin inhibitors in development at Lilly

Jan. 4, 1999

12-HETE inhibitor suppresses coronary thrombosis in dog model

Jan. 4, 1999

Warner-Lambert and BioChem Therapeutic seek potent and selective thrombin inhibitors

Dec. 30, 1998

Broader indication for Agrylin approved by FDA

Dec. 22, 1998

Orally bioavailable serine protease inhibitors for thrombotic disorders designed at Akzo

Dec. 22, 1998

Pharmacia & Upjohn to copromote Pletal tablets with Otsuka

Dec. 21, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 30, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026